Endovia Health Sciences, Inc. (EDVA) sold and issued 526,582 shares of common stock to C/M Capital Master Fund, LP on September 30, 2026, for total gross proceeds of $81,830.84 under a Securities Purchase Agreement dated September 19, 2025. To the extent the sales are deemed unregistered, Endovia stated they were made under the exemptions provided by Section 4(a)(2) and Rule 506(b); the purchaser’s resales were registered on a Form S-1 effective August 24, 2026.
Endovia Health Sciences, Inc. is asking stockholders to approve amendments to its 2025 Equity Incentive Plan, including a 4,815,780-share increase in authorized issuance in addition to formula-based plan amounts, and a reduction of certain prior option grants’ exercise price from $1.00 to $0.3551 per share. These changes are subject to stockholder approval.
If approved, an automatic feature would grant proportional RSUs in specified transactions to maintain Covered Persons’ collective ownership at 20% of fully diluted shares. Separate proposed RSU grants represent approximately 4,029,561 shares currently and also require stockholder approval. Endovia warns the maintenance grants could dilute other holders over time. It also says significant losses and negative cash flow require continued capital raising, including equity-linked securities, for working capital and an acquisition it says is needed to maintain its NYSE American listing.
Stockholders will vote on six proposals at the virtual annual meeting on November 20, 2026. Separately, Endovia says it paid $301,801 under a July 10, 2026 agreement, triggering release of $2,834,689 in obligations under its loan agreement.
Endovia Health Sciences, Inc. (EDVA), alongside Lupvindol BioSciences, announced that the FDA determined the proposed use of CannEpil, an investigational CBD and THC oral solution for pain associated with bone cancer in dogs, qualifies as a “minor use” under MUMS. This makes CannEpil eligible to pursue conditional approval; the FDA said minor-use status will be maintained through approval of the applicable New Animal Drug Application. CannEpil remains investigational and has not been approved or conditionally approved.
Endovia and Lupvindol are scheduled to meet formally with the FDA on November 19, 2026, to discuss the development program, including studies, manufacturing requirements and regulatory submissions. The companies are sourcing and finalizing U.S.-based manufacturing capabilities. A potential veterinary launch in 2027 is subject to regulatory approvals, manufacturing readiness and other factors.
Endovia Health Sciences, Inc. entered into a letter agreement with C/M Capital Master Fund, LP, which committed to invest a minimum of $1 million to support CannEpil regulatory advancement, clinical development planning and commercialization. Endovia closed an initial investment of $510,000 in exchange for a secured convertible note with $576,271 principal, including a $66,271 original issue discount. The note converts at the lower of $1.75 per share or $0.01 above the closing sale price on the conversion date.
The note matures on September 18, 2027, carries no interest except upon default, when interest accrues at 7% per annum, and may be prepaid without premium or penalty. It is also subject to mandatory prepayments of 30% of gross proceeds received from securities issued under the September 19, 2025 equity line of credit facility. From August 31, 2026 through September 23, 2026, Endovia issued 3,629,250 common shares to the investor under that facility for $808,829.42 in gross proceeds.
Endovia Health Sciences, Inc. is seeking stockholder votes at its November 20, 2026 virtual annual meeting, including on amendments to its 2025 Equity Incentive Plan and related restricted stock unit (RSU) grants. Subject to approval, the amendments would add 4,815,780 shares beyond formula-based reserve increases and shares for automatic grants, and reprice prior options to $0.3551 per share from $1.00. The separate RSU proposal would represent 20% of fully diluted shares, presently approximately 2,093,250 shares, and also requires approval.
If approved, automatic grants would seek to keep covered persons collectively at 20% of fully diluted shares following specified transactions, including financings and acquisitions. Endovia says the feature could cause ongoing, potentially significant dilution to other stockholders. The company also says significant losses and negative cash flow require continued capital raising. Separately, Endovia reports making a $301,801 payment under its July 10, 2026 agreement, which provides for discharge of $2,834,689 in obligations upon lender receipt; the agreement set an August 31, 2026 payment deadline. The Board recommends voting FOR each proposal. A one-for-four reverse split took effect July 24, 2026.
Endovia Health Sciences, Inc. (EDVA) closed $500,000 of initial secured convertible debt funding from C/M Capital Master Fund, LP, representing the first tranche of a previously announced $1 million investment commitment linked to its exclusive global licensing agreement for the cannabinoid pharmaceutical candidate CannEpil®.
The new capital is intended to support development and commercialization of CannEpil®, including an FDA-regulated veterinary program for management of cancer-related pain in companion animals and international commercialization initiatives. The U.S. FDA Center for Veterinary Medicine has already opened INAD File No. 14145 for CannEpil®, formally starting the investigational veterinary drug process.
Endovia highlights growing federal focus on botanical and plant-derived medicines, citing an FDA initiative on botanical drug development and proposed House bill H.R. 10150, which would grant qualifying botanical drugs approved under Section 505(b)(1) a 12-year market exclusivity period. The company views this policy momentum as supportive of its broader cannabinoid health sciences strategy.
Endovia Health Sciences, Inc. (EDVA) is calling a virtual-only 2026 annual stockholders meeting to elect four directors, ratify Rose, Snyder & Jacobs LLP as auditor, hold an advisory say‑on‑pay vote, and consider major revisions to its 2025 Equity Incentive Plan and new RSU grants.
The equity plan amendments would add 4,815,780 shares to the plan’s share reserve, reprice previously granted options from $1.00 to $0.3551 per share, and add an Automatic Ownership Maintenance mechanism intended to keep specified insiders and advisors at 20% of fully diluted shares via ongoing RSU grants. A separate proposal seeks approval of RSU grants sized at 20% of fully diluted shares (about 2,093,250 RSUs at the time described). The company discloses that this structure could cause substantial, ongoing dilution to other stockholders as equity is issued in future financings and transactions. Endovia also describes a July 2026 letter agreement under which it can extinguish approximately $2.83 million of obligations under a revenue loan in exchange for a $301,801 payment, significantly reducing secured debt if completed.
SPLASH BEVERAGE GROUP, INC. (EDVA), now operating as Endovia Health Sciences, reports on U.S. federal moves toward rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act and explains how this supports its cannabinoid-focused strategy.
The company expects to submit a CannEpil® FDA "Z submission" and request a pre-submission conference in the coming week, aiming to advance its proprietary cannabinoid formulation through FDA pathways. It is also reviewing additional cannabinoid-based formulations and IP for potential licensing, acquisition or collaboration, and is working with capital partners to finalize expanded financing to support development and potential transactions. The rebrand to Endovia Health Sciences and ticker EDVA became effective on the NYSE American on August 24, 2026.
SPLASH BEVERAGE GROUP, INC. (symbol EDVA), whose registrant name in this report is Endovia Health Sciences, Inc., reported an unregistered equity financing. On August 25, 2026, the company sold and issued 510,951 shares of common stock to C/M Capital Master Fund, LP under a previously executed Securities Purchase Agreement dated September 19, 2025, generating gross proceeds of $107,610.62.
The shares were issued in reliance on exemptions from registration under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b). The purchaser’s resales of these shares are covered by the company’s Form S-1 registration statement (File No. 333-298112), which became effective on August 24, 2026.
Endovia Health Sciences, Inc. (EDVA) filed a resale prospectus covering up to 5,000,000 shares of common stock issuable to C/M Capital Master Fund, LP under an equity line of credit Securities Purchase Agreement. These shares may be resold by C/M from time to time, while Endovia is not directly selling shares under this prospectus.
Endovia may receive up to $30,782,793 in gross proceeds from its discretionary sales of stock to C/M, to be used for working capital, resolving disputes, paying outstanding amounts and general corporate purposes. Common shares outstanding would increase from 6,412,521 to 11,412,521 if all purchase shares are issued.
The company has shifted from a beverage focus to cannabinoid and wellness, licensing exclusive worldwide rights to the CBD/THC product CannEpil®. It effected a 1-for-4 reverse stock split effective July 24, 2026. Auditors have raised substantial doubt about Endovia’s ability to continue as a going concern, and NYSE American has accepted a compliance plan after stockholders’ equity stood at ($15,300,828), below the $6 million requirement, creating delisting risk.